Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.
Profitability
This table compares Larimar Therapeutics and Caribou Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Larimar Therapeutics | N/A | -137.39% | -97.65% |
| Caribou Biosciences | -1,030.42% | -89.11% | -62.47% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Larimar Therapeutics and Caribou Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Larimar Therapeutics | 1 | 0 | 6 | 3 | 3.10 |
| Caribou Biosciences | 1 | 0 | 3 | 1 | 2.80 |
Risk and Volatility
Larimar Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.
Institutional & Insider Ownership
91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 4.0% of Larimar Therapeutics shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Larimar Therapeutics and Caribou Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Larimar Therapeutics | N/A | N/A | -$165.67 million | ($1.95) | -2.08 |
| Caribou Biosciences | $11.16 million | 15.90 | -$148.12 million | ($1.08) | -1.53 |
Caribou Biosciences has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Caribou Biosciences beats Larimar Therapeutics on 9 of the 14 factors compared between the two stocks.
About Larimar Therapeutics
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
